| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Specific target information for Yadanzioside F is not extensively reported in the available literature. As a quassinoid compound, it is expected to share similar mechanisms of action with other quassinoids, which may include inhibition of protein synthesis, induction of apoptosis, and modulation of inflammatory pathways. Further research is needed to identify and characterize its primary molecular targets.
|
|---|---|
| ln Vitro |
Yadanzioside F has been reported to show antileukemic activity. As a quassinoid compound, it is expected to exhibit additional biological activities including antitumor, antimalarial, and anti-inflammatory properties. Further studies are needed to fully characterize its in vitro pharmacological profile and to determine its potency against various cancer cell lines.
|
| ln Vivo |
Specific in vivo activity data for Yadanzioside F are not extensively reported in the available literature. As a quassinoid compound with antileukemic activity, it may exhibit efficacy in preclinical models of leukemia and other cancers. Further research is needed to characterize its pharmacokinetic and pharmacodynamic profiles in animal models.
|
| Enzyme Assay |
The in vitro assay for Yadanzioside F typically involves standard biochemical or cellular assays used for quassinoid compounds. These may include enzyme inhibition assays, cell viability assays, or receptor binding studies. The compound is tested at various concentrations, and the biological activity is quantified using appropriate readouts such as IC50 or EC50 values.
|
| Cell Assay |
The in vitro cellular assay for Yadanzioside F typically involves culturing leukemia cell lines or other relevant cancer cell types in appropriate growth media. Cells are treated with varying concentrations of the compound, and cell viability is assessed using standard assays such as MTT, SRB, or CellTiter-Glo. The antiproliferative effect is quantified by determining the half-maximal inhibitory concentration (IC50).
|
| Animal Protocol |
In vivo animal studies for Yadanzioside F would typically involve the use of mouse xenograft models bearing human leukemia or other tumors. Tumor-bearing mice would be administered the compound via appropriate routes (e.g., oral gavage or intraperitoneal injection) at various dose levels. Tumor growth inhibition would be monitored over several weeks, and endpoints would include tumor volume measurements, body weight changes, and histopathological analysis of tumor tissues.
|
| ADME/Pharmacokinetics |
Yadanzioside F has a molecular weight of 642.60 g/mol and a molecular formula of C29H38O16. The IUPAC name is methyl (1R,2S,3R,6R,8S,9S,13S,14R,15R,16S)-3-acetyloxy-15,16-dihydroxy-9,13-dimethyl-4,10-dioxo-11-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5,18-dioxapentacyclo[12.5.0.01,6.02,17.08,13]nonadec-11-ene-17-carboxylate. The compound has a purity of ≥98%.
|
| Toxicity/Toxicokinetics |
Specific toxicology data for Yadanzioside F are not available in the public domain. The compound is intended for research use only and should be handled with appropriate laboratory safety precautions. As a toxic component of Brucea javanica, it should be handled with extra caution. Standard safety assessments would be required before any clinical application.
|
| References | |
| Additional Infomation |
It has been reported that methyl (1R,2S,3R,6R,8S,9S,13S,14R,15R,16S)-3-acetoxy-15,16-dihydroxy-9,13-dimethyl-4,10-dioxo-11-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxecyclo-2-yl]oxy-5,18-dioxapentane[12.5.0.01,6.02,17.08,13]nonadecan-11-en-17-carboxylic acid ester exists in the Brucea javanica, and relevant data are available.
Yadanzioside F is a quassinoid compound extracted from the seeds of Brucea javanica. It has been reported to show antileukemic activity. The compound is also known by the synonyms Picras-1-en-21-oic acid, 15-(acetyloxy)-11,12-dihydroxy-3,16-dioxo-13,20-epoxy-2-(beta-D-glucopyranosyloxy)-, methyl ester, (11-beta,12-alpha,15-beta)- and Aids-026367. It has not yet entered clinical trials and is strictly for preclinical research purposes. |
| Molecular Formula |
C29H38O16
|
|---|---|
| Molecular Weight |
642.60242
|
| Exact Mass |
642.216
|
| CAS # |
95258-11-0
|
| PubChem CID |
72955
|
| Appearance |
White to off-white solid powder
|
| LogP |
-1.3
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
45
|
| Complexity |
1320
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
C[C@H]1[C@@H]2C[C@@H]3[C@@]45COC([C@@H]4[C@H](C(=O)O3)OC(=O)C)([C@H]([C@@H]([C@@H]5[C@]2(C=C(C1=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)O)O)C(=O)OC
|
| InChi Key |
BYBDRFPMKPUWDZ-TXPSYQKCSA-N
|
| InChi Code |
InChI=1S/C29H38O16/c1-9-11-5-14-28-8-41-29(26(39)40-4,22(28)20(24(38)45-14)42-10(2)31)23(37)19(36)21(28)27(11,3)6-12(15(9)32)43-25-18(35)17(34)16(33)13(7-30)44-25/h6,9,11,13-14,16-23,25,30,33-37H,5,7-8H2,1-4H3/t9-,11-,13+,14+,16+,17-,18+,19+,20+,21+,22+,23-,25+,27-,28+,29?/m0/s1
|
| Chemical Name |
methyl (1R,2S,3R,6R,8S,9S,13S,14R,15R,16S)-3-acetyloxy-15,16-dihydroxy-9,13-dimethyl-4,10-dioxo-11-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5,18-dioxapentacyclo[12.5.0.01,6.02,17.08,13]nonadec-11-ene-17-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol : ~25 mg/mL (~38.90 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (1.95 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear EtOH stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (1.95 mM) (saturation unknown) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (1.95 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5562 mL | 7.7809 mL | 15.5618 mL | |
| 5 mM | 0.3112 mL | 1.5562 mL | 3.1124 mL | |
| 10 mM | 0.1556 mL | 0.7781 mL | 1.5562 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
